Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

被引：2

作者：

Arasanz, Hugo ^{[1
,2
]}

Chocarro, Luisa ^{[3
]}

Fernandez-Rubio, Leticia ^{[3
]}

Blanco, Ester ^{[3
,4
]}

Bocanegra, Ana ^{[3
]}

Echaide, Miriam ^{[3
]}

Labiano, Ibone ^{[2
]}

Huerta, Ana Elsa ^{[2
]}

Alsina, Maria ^{[1
,2
]}

Vera, Ruth ^{[1
,2
]}

Escors, David ^{[3
]}

Kochan, Grazyna ^{[3
]}

机构：

[1] Hosp Univ Navarra, Med Oncol Dept, Inst Invest Sanitaria Navarra IdiSNA, Pamplona 31008, Spain

[2] Inst Invest Sanitaria Navarra IdiSNA, Oncobiona Grp, Navarrabiomed, Pamplona 31008, Spain

[3] Inst Invest Sanitaria Navarra IdiSNA, Oncoimmunol Grp, Navarrabiomed, Pamplona 31008, Spain

[4] Inst Invest Sanitaria Navarra IdiSNA, Div Gene Therapy & Regulat Gene Express, Ctr Invest Med Aplicada CIMA, Pamplona 31008, Spain

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 12期

关键词：

lung cancer; bispecific; nanobodies; NSCLC; SCLC; targeted therapies; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; CHEMOTHERAPY; VEMURAFENIB; COBIMETINIB; MECHANISMS; NANOBODIES; NIVOLUMAB;

D O I：

10.3390/ijms24129855

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the underlying molecular routes, in particular, in oncogene-driven tumors. In this review, we present the current landscape of bispecific antibodies for the treatment of lung cancer and discuss potential scenarios where the role of these therapeutics might expand in the near future.

引用

页数：12

共 50 条

[21] Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects
Long Long
Chen Zhao
Muqimova Ozarina
Xianda Zhao
Jing Yang
Honglei Chen
Clinical Drug Investigation, 2019, 39 : 341 - 353
[22] Advanced gastric cancer: Current treatment landscape and future perspectives
Digklia, Antonia
Wagner, Anna Dorothea
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (08) : 2403 - 2414
[23] Advanced gastric cancer:Current treatment landscape and future perspectives
Antonia Digklia
Anna Dorothea Wagner
World Journal of Gastroenterology, 2016, (08) : 2403 - 2414
[24] Bispecific antibodies: what future?
Pelegrin, Andre
Robert, Bruno
M S-MEDECINE SCIENCES, 2009, 25 (12): : 1155 - 1157
[25] The landscape of bispecific T cell engager in cancer treatment
Zhou, Shujie
Liu, Mingguo
Ren, Fei
Meng, Xiangjiao
Yu, Jinming
BIOMARKER RESEARCH, 2021, 9 (01)
[26] The landscape of bispecific T cell engager in cancer treatment
Shujie Zhou
Mingguo Liu
Fei Ren
Xiangjiao Meng
Jinming Yu
Biomarker Research, 9
[27] Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
Heitmann, Jonas S.
Pfluegler, Martin
Jung, Gundram
Salih, Helmut R.
CANCERS, 2021, 13 (03) : 1 - 17
[28] Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review
Khosla, Atulya Aman
Jatwani, Karan
Singh, Rohit
Reddy, Aswanth
Jaiyesimi, Ishmael
Desai, Aakash
PHARMACEUTICALS, 2023, 16 (10)
[29] Aromatase inhibitors: Current indications and future prospects for treatment of postmenopausal breast cancer
Arora, A
Potter, JF
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (04) : 611 - 616
[30] Cryoablation for the Treatment of Breast Cancer: A Review of the Current Landscape and Future Possibilities
Pigg, Nicholas
Ward, Robert C.
ACADEMIC RADIOLOGY, 2023, 30 (12) : 3086 - 3100

← 1 2 3 4 5 →